{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Blesl A"],"funding":["Austrian National Bank","Austrian Society of Gastroenterology and Hepatology"],"pagination":["9-19"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10769779"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(1)"],"pubmed_abstract":["Background
Corticosteroids are used for induction of remission in patients with moderately to severely active ulcerative colitis. However, up to one-third of patients fail to this therapy. We investigated if fecal microbial composition or its metabolic capacity are associated with response to systemic corticosteroids.Methods
In this prospective, multicenter study, patients with active ulcerative colitis (Lichtiger score ≥4) receiving systemic corticosteroids were eligible. Data were assessed and fecal samples collected before and after 4 weeks of treatment. Patients were divided into responders (decrease of Lichtiger Score ≥50%) and nonresponders. The fecal microbiome was assessed by the 16S rRNA gene marker and analyzed with QIIME 2. Microbial metabolic pathways were predi"],"journal":["Inflammatory bowel diseases"],"pubmed_title":["Prediction of Response to Systemic Corticosteroids in Active UC by Microbial Composition-A Prospective Multicenter Study."],"pmcid":["PMC10769779"],"funding_grant_id":["DFG RU5042","01ZX1915A","17936"],"pubmed_authors":["Reinisch W","Watschinger C","Kump P","Aden K","Mayer A","Hogenauer C","Tillinger W","Binder L","Ludwiczek O","Koch R","Reider S","Moschen A","Blesl A","Haas T","Grochenig HP","Novacek G","Furst S","Primas C","Reicht G","Waschina S","Kutschera M","Wurm P","Hennlich B","Gorkiewicz G","Miehsler W","Illiasch C","Steidl K","Steiner P"],"additional_accession":[]},"is_claimable":false,"name":"Prediction of Response to Systemic Corticosteroids in Active UC by Microbial Composition-A Prospective Multicenter Study.","description":"Background
Corticosteroids are used for induction of remission in patients with moderately to severely active ulcerative colitis. However, up to one-third of patients fail to this therapy. We investigated if fecal microbial composition or its metabolic capacity are associated with response to systemic corticosteroids.Methods
In this prospective, multicenter study, patients with active ulcerative colitis (Lichtiger score ≥4) receiving systemic corticosteroids were eligible. Data were assessed and fecal samples collected before and after 4 weeks of treatment. Patients were divided into responders (decrease of Lichtiger Score ≥50%) and nonresponders. The fecal microbiome was assessed by the 16S rRNA gene marker and analyzed with QIIME 2. Microbial metabolic pathways were predi","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jan","modification":"2026-06-01T21:51:14.804Z","creation":"2024-12-04T10:29:21.583Z"},"accession":"S-EPMC10769779","cross_references":{"pubmed":["37463118"],"doi":["10.1093/ibd/izad126"]}}